Prevention and control of seasonal influenza with vaccines : recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014
Published Date:September 20, 2013
Corporate Authors:National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office. ; National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division. ; United States. Advisory Committee on Immunization Practices.
Influenza, Human/prevention & Control
Influenza A Virus, H1N1 Subtype/immunology
Influenza A Virus, H3N2 Subtype/immunology
Influenza B Virus/immunology
Influenza Vaccines/administration & Dosage
Influenza Vaccines/adverse Effects
Influenza Vaccines/supply & Distribution
Pneumococcal Vaccines/administration & Dosage
Pneumococcal Vaccines/adverse Effects
Series:MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 62, RR-07
Description:This report updates the 2012 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccines for the prevention and control of seasonal influenza (CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2012;61:613-8). Routine annual influenza vaccination is recommended for all persons aged ?6 months. For the 2013-14 influenza season, it is expected that trivalent live attenuated influenza vaccine (LAIV3) will be replaced by a quadrivalent LAIV formulation (LAIV4). Inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations. Vaccine virus strains included in the 2013-14 U.S. trivalent influenza vaccines will be an A/California/7/2009 (H1N1)-like virus, an H3N2 virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011, and a B/Massachusetts/2/2012-like virus. Quadrivalent vaccines will include an additional influenza B virus strain, a B/Brisbane/60/2008-like virus, intended to ensure that both influenza B virus antigenic lineages (Victoria and Yamagata) are included in the vaccine. This report describes recently approved vaccines, including LAIV4, IIV4, trivalent cell culture-based inactivated influenza vaccine (ccIIV3), and trivalent recombinant influenza vaccine (RIV3). No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one product is otherwise appropriate. This information is intended for vaccination providers, immunization program personnel, and public health personnel. These recommendations and other information are available at CDC's influenza website (http://www.cdc.gov/flu); any updates also will be found at this website. Vaccination and health-care providers should check the CDC influenza website periodically for additional information. Introduction -- Methods -- Primary changes and updates in the recommendations -- Background and epidemiology -- Influenza vaccine effectiveness -- Safety of influenza vaccines -- Dosage, administration, and storage of influenza vaccines -- Influenza vaccine composition for the 2013-14 season -- New and recently approved influenza vaccine products -- Recommendations for the use of influenza vaccines, 2013-14 influenza season -- Sources of information regarding influenza and surveillance -- Additional information regarding prevention of influenza in specific populations -- References. The material in this report originated in the National Center for Immunization and Respiratory Diseases, Influenza Division, and the National Center for Emerging and Zoonotic Infectious Diseases, Immunization Safety Office. 43 p.
Supporting Files:No Additional Files
You May Also Like: